Advertisement

Citations to this article

Abstract

Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas. pSTAT3 is found in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR. Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, whereas a pan-JAK inhibitor (P6) blocked activation of STAT3 and inhibited tumorigenesis. Cell lines expressing these persistently activated mutant EGFRs also produced high IL-6 levels, and blockade of the IL-6/gp130/JAK pathway led to a decrease in pSTAT3 levels. In addition, reduction of IL-6 levels by RNA interference led to a decrease in tumorigenesis. Introduction of persistently activated EGFR into immortalized breast epithelial cells led to tumorigenesis, IL-6 expression, and STAT3 activation, all of which could be inhibited with P6 or gp130 blockade. Furthermore, inhibition of EGFR activity in multiple cell lines partially blocked transcription of IL-6 and concurrently decreased production and release of IL-6. Finally, immunohistochemical analysis revealed a positive correlation between pSTAT3 and IL-6 positivity in primary lung adenocarcinomas. Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by means of IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment.

Authors

Sizhi Paul Gao ... Bayard Clarkson, Jacqueline F. Bromberg

×

Total citations by year in Crossref

Year: 2014 2013 2012 2011 2010 2009 2008 Total
Citations: 20 21 19 12 13 16 4 105
Citation information

Citations to this article in Crossref (105)

Title and authors Publication Year
Radioimmunoimaging with Mixed Monoclonal Antibodies of Nude Mice Bearing Human Lung Adenocarcinoma Xenografts
D Duan, SL Li, YQ Zhu, T Zhang, CM Lei, XH Cheng
Asian Pacific Journal of Cancer Prevention 2012
STAT3 as a therapeutic target for Epstein-Barr virus (EBV) – associated nasopharyngeal carcinoma
Y Ho, SW Tsao, M Zeng, VW Lui
Cancer Letters 2012
Overexpression of signal transducer and activator of transcription (STAT-3 and STAT-5) transcription factors and alteration of suppressor of cytokine signaling (SOCS-1) protein in prostate cancer
N Singh, S Hussain, M Bharadwaj, N Kakkar, SK Singh, RC Sobti
Journal of Receptors and Signal Transduction 2012
DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors
UJ Yun, SE Park, YS Jo, J Kim, DY Shin
Cancer Letters 2012
PNAS Plus: STAT3 negatively regulates thyroid tumorigenesis
JP Couto, L Daly, A Almeida, JA Knauf, JA Fagin, M Sobrinho-Simoes, J Lima, V Maximo, P Soares, D Lyden, JF Bromberg
Proceedings of the National Academy of Sciences 2012
Interleukin-6 signaling pathway in targeted therapy for cancer
Y Guo, F Xu, TJ Lu, Z Duan, Z Zhang
Cancer Treatment Reviews 2012
Involvement of STAT3, NF-κB and associated downstream molecules before and after the onset of urethane induced lung tumors in mouse
M Pandey, KP Gupta
Environmental Toxicology and Pharmacology 2012
ER stress-induced inflammation: does it aid or impede disease progression?
AD Garg, A Kaczmarek, O Krysko, P Vandenabeele, DV Krysko, P Agostinis
Trends in Molecular Medicine 2012
The role of pseudokinases in cancer
H Zhang, A Photiou, G Arnhild, J Stebbing, G Giamas
Cellular Signalling 2012
Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway
HS Hsu, JH Lin, TW Hsu, K Su, CW Wang, KY Yang, SH Chiou, SC Hung
Lung Cancer 2012
Notch-Induced hIL-6 Production Facilitates the Maintenance of Self-Renewal of hCD34+ Cord Blood Cells Through the Activation of Jak-PI3K-STAT3 Pathway
B Choi, E Chun, SY Kim, M Kim, KY Lee, SJ Kim
The American Journal of Pathology 2011
Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer
D Drygin, CB Ho, M Omori, J Bliesath, C Proffitt, R Rice, A Siddiqui-Jain, S O’Brien, C Padgett, JK Lim, K Anderes, WG Rice, D Ryckman
Biochemical and Biophysical Research Communications 2011
Rapid Symptomatic Improvement in Gefitinib-Treated Patients with EGFR-Mutated Lung Cancer: Possible Role of Downregulation of Inflammatory Molecules?
EN Suspitsin, EV Levchenko, FV Moiseyenko, AO Ivantsov, SA Radzhabova, DE Matsko, VM Moiseyenko, EN Imyanitov
Onkologie 2011
Inflamm-aging of the stem cell niche: Breast cancer as a paradigmatic example : Breakdown of the multi-shell cytokine network fuels cancer in aged people
M Bonafè, G Storci, C Franceschi
BioEssays 2011
CK2 Inhibitors Enhance the Radiosensitivity of Human Non-Small Cell Lung Cancer Cells Through Inhibition of Stat3 Activation
YC Lin, MS Hung, CK Lin, JM Li, KD Lee, YC Li, MF Chen, JK Chen, CT Yang
Cancer Biotherapy & Radiopharmaceuticals 2011
Mathematical model of the role of intercellular signalling in intercellular cooperation during tumorigenesis
S Ghosh, S Elankumaran, IK Puri
Cell Proliferation 2011
STAT3 expression in activating EGFR-driven adenocarcinoma of the lung
S Takata, N Takigawa, Y Segawa, T Kubo, K Ohashi, T Kozuki, N Teramoto, M Yamashita, S Toyooka, M Tanimoto, K Kiura
Lung Cancer 2011
Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs
IK Guttilla, KN Phoenix, X Hong, JS Tirnauer, KP Claffey, BA White
Breast Cancer Research and Treatment 2011
The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
A Chalaris, C Garbers, B Rabe, S Rose-John, J Scheller
European Journal of Cell Biology 2011
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells
I Kryczek, S Liu, M Roh, L Vatan, W Szeliga, S Wei, M Banerjee, Y Mao, J Kotarski, MS Wicha, R Liu, W Zou
International Journal of Cancer 2011
Blocking the IL-6–STAT3 signaling pathway: potential liver cancer therapy
Y Liu, J Lin
Future Oncology 2011
Correlation of Activated STAT3 Expression with Clinicopathologic Features in Lung Adenocarcinoma and Squamous Cell Carcinoma
R Jiang, Z Jin, Z Liu, L Sun, L Wang, K Li
Molecular diagnosis & therapy 2011
Ultraviolet light induces Stat3 activation in human keratinocytes and fibroblasts through reactive oxygen species and DNA damage
T Bito, N Sumita, T Masaki, T Shirakawa, M Ueda, R Yoshiki, Y Tokura, C Nishigori
Experimental Dermatology 2010
SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo
WR Chao, K Amin, Y Shi, P Hobbs, M Tanabe, M Tanga, L Jong, N Collins, R Peters, K Laderoute, D Dinh, D Yean, C Hou, B Sato, C Alt, L Sambucetti
Angiogenesis 2010
Inflaming resistance to Tarceva
C Cain
Science-Business eXchange 2010

Advertisement
Advertisement